Purpose To identify the effect of the benzimidazalone derivative, NS1619, on modulating pulmonary vascular tone in lungs from rats exposed to normoxia (21 % FiO 2 ) or chronic hypoxia (10 % FiO 2 ) for three weeks. Methods Isolated perfused lungs were preconstricted (U46619), and dose-dependent vasodilation to NS1619 was assessed. To elucidate the mechanisms responsible, NS1619 vasodilatory responses were assessed following inhibition of large-conductance Ca 2? -activated (BK Ca ; iberiotoxin and paxilline), L-type Ca 2? (nifedipine), K ? (tetraethylammonium), Cl -(niflumic acid), and cation/TRP (lanthanum) channels, as well as nitric oxide synthase (L-NAME). Results Compared to normoxia, NS1619-induced vasodilation was significantly greater following hypoxia; however, NO-dependent vasodilation and BK Ca -mediated vasodilation, in response to NS1619, were similar in the normoxic and hypoxic lungs. In contrast, direct activation of L-type Ca 2? and non-BK Ca K ? channel was involved in the NS1619-induced vasodilation only in hypoxic lungs. Conclusions NS1619 causes pulmonary vasodilation by affecting multiple complementary pathways, including stimulation of NO production, activation of BK Ca channels, other TEA-sensitive K ? channels, and L-type Ca 2? channels, and could be considered as a therapeutic agent in hypoxic PH.
Introduction
The development of pulmonary hypertension (PH), particularly in response to prolonged hypoxia, is of critical importance in patients suffering from chronic lung diseases and is associated with significant morbidity and mortality [1] . The underlying pathophysiology of PH associated with chronic hypoxemia includes endothelial dysfunction, an enhanced vascular tone and vascular remodeling [2] [3] [4] . While the structural remodeling predominantly occurs in the large pulmonary arteries, the increase in pulmonary vascular resistance is largely attributed to pathological changes occurring within the precapillary arterioles. However, with the exception of supplemental oxygen therapy, there are currently no approved treatment strategies that effectively target the pulmonary resistance vasculature in PH-associated lung disease.
In hypoxia-induced PH, changes in the activity and expression of the L-type Ca 2? channels [5] , as well as voltage-gated (K v ) [6] and large-conductance Ca 2? -activated potassium channels (BK Ca ) [7, 8] , have been observed and contribute, in part, to an elevated vascular tone and hypersensitivity to vasoconstrictor stimuli [9] . Previously, we [10] , and others [11, 12] , have shown that the benzimidazalone derivative, NS1619, activates endothelial and vascular smooth muscle BK Ca channels, and causes both endothelialdependent and -independent vasodilation. Additionally, NS1619 has been reported to promote vasorelaxation through inhibitory actions on voltage-dependent Ca 2? channels [11, 13] . Hence, NS1619 has the potential to favorably alter the activity of pulmonary vascular ion channels that have been shown to be important in hypoxic lung vasculature. Therefore, the purpose of the current study was to determine the effect of NS1619 on pulmonary circulation in normoxic and chronically hypoxic animals using the isolated perfused lung technique and to elucidate the underlying mechanisms responsible for the differences observed within hypoxic lung vasculature.
Methods

Animals
All procedures were approved by the Animal Care and Use Committee at the Providence Veterans Affairs Medical Center and conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health. Adult male SpragueDawley rats (n = 87, *250 g; Charles River Laboratories, Wilmington, MA) were used in this study. Rats were housed at 23°C, maintained on a 12:12-h light/dark cycle in either normoxic (n = 38; 21 % FiO 2 ) or normobaric hypoxic (n = 49; 10 % FiO 2 , Biospherix A chamber ? Pro-Ox controller, Biospherix Ltd., Lacona, NY) environment for three weeks, and provided rat chow and water ad libitum.
Assessment of Pulmonary Hypertension and RV Hypertrophy
At the end of three weeks, the rats (n = 7/group) were anesthetized with isofluorane (2 %/O 2 balance) and a transthoracic echocardiogram (Visualsonics Vevo 2100, FUJI-FILM Visualsonics Inc., Toronto, Canada) was performed. The following measurements were obtained: pulmonary acceleration time measured on pulse-wave Doppler recording at the right ventricular outflow tract, RV-free wall thickness measured from M-Mode recording from parasternal views, LV ejection fraction measured on M-Mode from parasternal short axis view, and heart rate [14] .
Isolated Ventilated Perfused Lungs
At the end of three weeks, the rats were anesthetized (sodium pentobarbital, 60 mg/kg ip), injected with heparin, and the trachea was cannulated and connected to a volumecycled ventilator. Catheters were placed into the pulmonary artery (via the right ventricle) and left atrium (via the left ventricle) and secured. The heart and lungs were then trimmed free from the thorax and diaphragm, removed en bloc, and suspended. The pulmonary vasculature was continuously perfused at 7 ml/min with Earle's balanced salt solution, maintained at 37°C, and aerated with 95 % O 2 -5 % CO 2 [15] and 21 % O 2 /5 % CO 2 /74 % N 2 [16] for the normoxic and hypoxic lung preparations, respectively. Select experiments were repeated using 21 % O 2 /5 % CO 2 / 74 % N 2 aerated perfusate in normoxic lung preparations. A solution pH of 7.30-7.45 was maintained throughout the procedure.
Once suspended, the lungs were preconstricted with a thromboxane mimetic, U46619, until a pressor response (PAP U46619 -PAP Baseline ) of *10 mmHg was achieved and maintained. Peak PAP NS1619 was assessed following incremental doses of the putative BK Ca channel activator, NS1619 (3/30/150 lM), added to the perfusate. In select experiments, to isolate the mechanism of the NS1619-induced responses in determining PAP NS1619 , lung preparations were perfused with iberiotoxin (IbTx; 200 nM; BK Ca channel inhibitor [17] ) paxilline (3 lM; BK Ca channel inhibitor [18] ), tetraethylammonium (TEA; 10 mM; nonselective K ? channel blocker [10] ), L-NAME (100 lM; nitric oxide synthase inhibitor [10] ), lanthanum (La ; 100 lM; nonspecific cation/TRP channel blocker [10] ), niflumic acid (NFA; 30 lM; Cl -channel inhibitor [19] ), or nifedipine (1 lM; L-type Ca 2? channel blocker [19] ) prior to the addition of NS1619.
The baseline PAP (PAP Baseline ) at was calculated as a mean pressure over forty seconds prior to the addition of U46619. Data are reported as percent preconstriction, or percent vasorelaxation and are determined by the following equations;
All chemicals were obtained from Sigma Inc. (St. Louis, MO) with the exception of Ibtx, which was purchased from Anaspec (Fremont, CA).
Statistical Analysis
Dose-response curves were compared using a Student's t test, or repeated-measures two-way ANOVA with Tukey's post hoc analyses for pairwise comparisons, as appropriate. Values are expressed as means ± SE. Statistical significance was defined as P \ 0.05.
Results
Animal Characteristics
As expected, hypoxic rats weighed significantly less than their normoxic counterparts at the time of sacrifice (normoxic: 401.3 ± 7.6 g, hypoxic: 354.1 ± 8.3 g; P \ 0.05). Heart rate (normoxic: 376 ± 15 bpm vs. hypoxic: 363 ± 11 bpm; P = NS) and LV ejection fraction (normoxic: 87.6 ± 1.7 % vs. hypoxic: 86.5 ± 2.8 %; P = NS) were not significantly different between rats exposed to normoxia or hypoxia. However, RV thickness by echocardiogram (normoxic: 0.61 ± 0.06 mm vs. hypoxic: 1.5 ± 0.06 mm; P \ 0.05; n = 7) and RV/LV weight ratio (normoxic: 0.53 ± 0.02 vs. hypoxic: 0.87 ± 0.1; P \ 0/05; n = 4) was significantly higher, and pulmonary acceleration time (normoxic: 39.8 ± 1.5 ms vs. hypoxic: 25.9 ± 2.3 ms; P \ 0.05; n = 7) significantly lower, in hypoxic animals, validating the efficacy of the PH protocol.
NS1619-Induced Vasodilatory Response in Normoxic and Hypoxic Lungs
The selective BK Ca channel opener NS1619 elicited a dosedependent vasodilation in the U46619-preconstricted lungs from normoxic and hypoxic rats; however, NS1619-mediated vasodilation was significantly greater (*20 % more) in lungs from hypoxic animals compared to normoxic (Fig. 1a,  b) . Additionally, a subset (n = 4) of lungs perfused with 21 % O 2 /5 % CO 2 was investigated to assess the potential influence of variable perfusate O 2 concentrations as a confounding factor; however, the NS1619-mediated vasodilation remained significantly less compared to that observed in hypoxic lungs (63.8 ± 3.4 % of maximal vasoconstriction with 30 lM NS1619). Vasodilatory responses to the exogenous nitric oxide donor, sodium nitroprusside (SNP; 10 -9 -10 -4 M), elicited dose-dependent vasodilation within both groups, but there was no significant difference in SNPinduced dilation between groups (Fig. 1c) , confirming vasodilatory capacity was not affected by hypoxic conditions.
Differential Effect of Ion Channel Blockers on NS1619-Mediated Vasodilation in Hypoxic Lungs
The mechanism underlying the vasodilatory effect of BK Ca channel activation is membrane hyperpolarization, and the concomitant inhibition of L-type Ca 2? channels, in vascular smooth muscle cells [20] . Hence, we tested the effect of BK channel blocker, Ibtx, and L-type Ca 2? channel blocker, nifedipine, on NS1619-induced vasodilation. Pretreatment with Ibtx and nifedipine significantly attenuated NS1619-induced vasodilation in lung preparations from normoxic rats to a similar extent (Fig. 2a, b) . However, although Ibtx significantly attenuated the vasodilation in lungs from hypoxic animals (Fig. 2c, d) , the inhibition was significantly less compared to the effect of nifedipine (Fig. 2c, d ), suggesting that NS1619 causes vasodilation in hypoxic lungs, in part, by a non-BK Ca mechanism. Also, pretreatment of the lungs with paxilline, a structurally unrelated BK blocker, resulted in attenuation of vasodilation similar to that by Ibtx (normoxia: 64.7 ± 4.1 % vs. 76.0 ± 5.3 %, hypoxia: 42.2 ± 6.2 % vs. 50.2 ± 7.6 %, respectively).
In order to assess contribution of alternate potassium channels, we next compared the effect of Ibtx with a nonspecific potassium channel blocker, TEA, on NS1619-induced vasodilation. Both TEA and Ibtx caused similar attenuation of the NS1619-induced vasodilation in normoxic lung (Fig. 3a, b) . In contrast, TEA caused significantly more inhibition of NS1619-induced vasodilation in hypoxic lungs compared to Ibtx (Fig. 3a, b) , suggesting a role of non-BK Ca K ? channels in mediating the NS1619-induced vasodilation.
To determine if Cl -channel activation may underlie the effect of NS1619 in addition to K ? channels, we pretreated the lungs with Cl -channel blocker, NFA, in addition to TEA and observed no additional attenuation of the vasodilation with TEA alone (normoxia: 68.9 ± 5.8 % vs. 83.9 ± 7.0, hypoxia: 60.3 ± 5.3 % vs. 68.2 ± 5.8 %, respectively).
NO-Dependent Effects of NS1619
Since activation of BK Ca channels is associated with nitric oxide (NO) production in endothelial cells (related to an increase in intracellular Ca 2? [10] ), we next assessed the NO-dependent vasodilation in normoxic and hypoxic lungs. In both normoxic and hypoxic lungs, inhibition of NO production (L-NAME; Fig. 4a ) significantly reduced NS1619-induced vasodilation, compared to vehicle controls. However, the magnitude of reduction in both normoxic and hypoxic lungs was similar (Fig. 4b) . We have previously shown that NS1619 activates BK Ca channels in endothelial cells and causes NO release dependent on La 3? sensitive Ca 2? entry pathways [21] . Pretreatment of lungs with La 3? resulted in attenuation of NS1619-induced vasodilation (Fig. 4c ) similar to that of L-NAME (Fig. 4d) .
Discussion
While vascular remodeling is a critical component of PH associated with hypoxia [3, 4] , there is evidence to support that tonic vasoconstriction plays a significant role in the high pulmonary vascular resistance characteristic of PH [22] . Although vascular ion channels play an important role in vasoregulation of the pulmonary circulation [9] , there is significant heterogeneity in the distribution of ion channels between the macro-and microvasculature throughout the [23] . Furthermore, the expression and activity of several of these vascular ion channels is altered in chronically hypoxic lungs [5, 8, 9] . Hence, using an isolated perfused lung preparation, we sought to determine the effect of the benzimidazalone derivative, NS1619, on the vasoreactivity of the preconstricted pulmonary circulation and to identify the relative contribution of specific vascular ion channels in mediating the response in both normoxic and chronically hypoxic lungs. Our results demonstrate that the NS1619 causes significantly higher vasodilatory response in lungs from hypoxic animals. Furthermore, we show that the NS1619-induced vasodilation exhibits both NO-dependent and NO-independent components and is primarily mediated via effects on vascular K
? and L-type Ca 2? channels. Current therapies in pulmonary hypertension target vascular L-type Ca 2? channels, endothelin pathway, or nitric oxide pathway. Our observations suggest that another approach may be to study small molecules such as NS1619 that favorably affect pulmonary vascular function by targeting multiple pathophysiologically relevant pathways. Further studies in preclinical models are needed to confirm this approach and compare it to other available therapies.
BK Ca channels present in the pulmonary vascular endothelial (PVEC) and smooth muscle cells (PVSMC) open in response to depolarization and elevated intracellular calcium ([Ca 2? ] i ) levels, resulting in membrane hyperpolarization [20] . In endothelial cells, the hyperpolarization may result in a further increase in [Ca 2? ] i , resulting in release of vasodilatory mediators such as NO [24] ; whilst within vascular smooth muscle cells, the hyperpolarization can promote vasodilation by decreasing the activity of voltage-dependent L-type Ca 2? channels [25] . In chronic hypoxia, BK Ca channel activation has been shown to underlie the vasodilatory and anti-mitogenic effects of carbon monoxide inhalation [26] and dehydroepiandrosterone (DHEA) administration [27] , respectively. Correspondingly, we found that activation of BK Ca channels resulted in vasodilation of the pulmonary vasculature from both normoxic and hypoxic animals (*29 % in normoxia and 25 % in hypoxic lungs). Although it has been demonstrated that chronic hypoxia promotes an increased expression of BK Ca channels in rat PVSMC [8] , in the current study, the activation of the channels with NS1619 did not show an increased BK Ca -mediated vasodilation in the hypoxic lungs. This apparent discrepancy may be related to the observation that the BK Ca channels already have a higher basal activity in settings of hypoxia, which is considered to be a compensatory mechanism associated with increased b1-subunit expression [8] and increased intracellular calcium levels in PVSMC [28] .
Nitric oxide plays an important role in pulmonary vascular reactivity and is considered a therapeutic target in pulmonary hypertension [29] . Previously, we have demonstrated a NS1619-induced hyperpolarization of PVEC and increased NO production in vivo [10] and that the hyperpolarization is attenuated by blocking nonspecific cation channels in vitro [21] . Consistent with the mechanism we previously observed in cell culture [21] , pretreatment with L-NAME (NOS inhibitor) and La 3? (TRP inhibitor) attenuated the NS1619-induced vasodilation, suggesting that the NS1619-induced vasodilation is partly endothelial dependent and related to an increase in extracellular Ca 2? entry within the endothelium. However, in the current study, there was no apparent Fig. 4 Concentration-response relation of isolated perfused lungs from normoxic and hypoxic rats (n = 4-5/group) to NS1619 in the absence (vehicle) and presence of (a) L-NAME (100 lM; nitric oxide synthase inhibitor) and (c) lanthanum (La difference in the endothelial-dependent vasodilation between the normoxic and hypoxic lungs. Prior studies have demonstrated that eNOS expression and activity are augmented in hypoxic lungs and result in enhanced endothelial-dependent vasodilation in response to certain vasodilators, such as histamine [30] . In contrast, exogenous NO donors show an impaired vasodilatory response in hypoxic lungs likely due to endothelium-derived ROS and ET-1 counteracting the actions of exogenous NO in hypoxic lungs [31] . These studies suggest that in order to improve endothelium-dependent vasodilation, a simultaneous increase in NO release and inhibition of endothelial ROS and ET-1 may be required. In the current study, we did not observe an enhanced NO-dependent vasodilation in hypoxic lungs in response to NS1619. It is possible that although NS1619 increases NO release in hypoxic vasculature, it may not directly affect ROS and/or ET-1 release similar to other endothelial-dependent vasodilators, such as histamine.
Thus, we found that the extent of NO-dependent vasodilation and BK Ca -mediated vasodilation, in response to NS1619, was similar in the normoxic and hypoxic lungs. However, pretreatment with L-type Ca 2? channel blocker, nifedipine, had a larger inhibitory effect in hypoxic lungs than in normoxic lungs. This would be expected as a result of NS1619 inhibiting either L-type Ca 2? channels directly or by activating other K ? channels in VSMC resulting in hyperpolarization and indirect inhibition of L-type Ca 2? channels. We find that pretreatment with TEA, a BK Ca , and nonspecific K ? channel blocker had similar effect as nifedipine in hypoxic lungs and caused significantly more inhibition than Ibtx alone. Hence, it would appear the higher NS1619-induced vasodilation in hypoxia could be a result of activation of other TEA-sensitive PVSMC K ? channels involved in the hypoxic pulmonary vasoconstrictor response, such as K v 2.1 [32, 33] .
The results from our study have to be interpreted in context of certain limitations. Since we did not simultaneously block both L-type Ca 2? channels and K ? channels, it is possible that some effect of NS1619 is mediated by direct inhibition of L-type Ca 2? channels that have been shown to be upregulated in hypoxic lungs as well [5] . Also, we chose to use similar pressor response instead of similar U46619 doses as previously used by others [30] in our preconstriction protocol. Hence, we cannot completely rule out that use of varying doses of U46619 could have had an effect on subsequent dose-response curves. Although we performed select experiments with 21 % O 2 perfusate conditions to demonstrate that NS1619 response remained significantly higher in chronically hypoxic lungs as with 95 % O 2 perfusate conditions, we cannot rule out the effect of 21 % O 2 perfusate in chronically hypoxic lungs on the dose responsiveness of NS1619 in presence of other inhibitors.
In conclusion, we demonstrate that NS1619 causes robust vasodilation in the pulmonary circulation that is further accentuated in lungs from hypoxic animals. Also, NS1619 mediated the vasodilation by affecting multiple complementary pathways including stimulation of NO production, activation of BK Ca channels, other TEA-sensitive K
? channels, and L-type Ca 2? channels. Hence, compounds such as NS1619 represent a novel therapeutic strategy of targeting multiple channels in hypoxic pulmonary hypertension and could be considered for further preclinical evaluation.
